![](/img/cover-not-exists.png)
Immune response from STRIDE, a randomized, Phase II, open-label study of sipuleucel-T (sip-T) with concurrent vs sequential enzalutamide (enz) administration in metastatic castration-resistant prostate cancer (mCRPC)
Drake, Charles G, Quinn, David, Dreicer, Robert, Antonarakis, Emmanuel, Shore, Neal, Corman, John, Concepcion, Raoul, Pieczonka, Christopher, Campogan, Dwayne, Fan, Li-Qun, Chang, Nancy, Sheikh, NadeeVolume:
3
Year:
2015
Language:
english
Journal:
Journal for ImmunoTherapy of Cancer
DOI:
10.1186/2051-1426-3-S2-P145
File:
PDF, 253 KB
english, 2015